- Home
- NRIX vs CCBG Comparison
NRIX vs CCBG Comparison
Compare NRIX & CCBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- CCBG
- Stock Information
- Founded
- NRIX 2009
- CCBG 1895
- Country
- NRIX United States
- CCBG United States
- Employees
- NRIX N/A
- CCBG N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- CCBG Major Banks
- Sector
- NRIX Health Care
- CCBG Finance
- Exchange
- NRIX Nasdaq
- CCBG Nasdaq
- Market Cap
- NRIX 728.6M
- CCBG 733.2M
- IPO Year
- NRIX 2020
- CCBG N/A
- Fundamental
- Price
- NRIX $9.91
- CCBG $43.48
- Analyst Decision
- NRIX Strong Buy
- CCBG Buy
- Analyst Count
- NRIX 15
- CCBG 1
- Target Price
- NRIX $29.13
- CCBG $45.00
- AVG Volume (30 Days)
- NRIX 733.8K
- CCBG 35.0K
- Earning Date
- NRIX 10-10-2025
- CCBG 10-21-2025
- Dividend Yield
- NRIX N/A
- CCBG 2.21%
- EPS Growth
- NRIX N/A
- CCBG 14.00
- EPS
- NRIX N/A
- CCBG 3.42
- Revenue
- NRIX $88,381,000.00
- CCBG $240,944,000.00
- Revenue This Year
- NRIX $74.59
- CCBG $11.91
- Revenue Next Year
- NRIX N/A
- CCBG $3.57
- P/E Ratio
- NRIX N/A
- CCBG $12.71
- Revenue Growth
- NRIX 41.86
- CCBG 8.96
- 52 Week Low
- NRIX $8.18
- CCBG $32.38
- 52 Week High
- NRIX $29.56
- CCBG $44.69
- Technical
- Relative Strength Index (RSI)
- NRIX 47.82
- CCBG 61.24
- Support Level
- NRIX $8.97
- CCBG $42.96
- Resistance Level
- NRIX $9.68
- CCBG $44.04
- Average True Range (ATR)
- NRIX 0.55
- CCBG 0.86
- MACD
- NRIX 0.04
- CCBG 0.15
- Stochastic Oscillator
- NRIX 55.13
- CCBG 75.36
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.